The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
MHLW Presents Draft Optimal Use Guidelines for Keytruda: Chuikyo
The Ministry of Health, Labor and Welfare (MHLW) on January 25 presented a draft of “optimal use promotion guidelines” for anti-PD-1 antibody Keytruda (pembrolizumab) for the treatment of non-small cell lung cancer (NSCLC). The draft guidelines, tendered to the Central…
To read the full story
Related Article
- MHLW Lays Out Chuikyo Discussion Timeline for Drug Pricing Overhaul
January 26, 2017
- Industry Wants Simplified Rule, Limited Application for Foreign Price Adjustment: Chuikyo
January 26, 2017
- Chuikyo on Alert for Trump’s Possible Pressure on Drug Front
January 26, 2017
- (Update) Chuikyo Agrees to Shed US Price from Foreign Price Adjustment Rule
January 25, 2017
- PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
December 15, 2016
REGULATORY
- Japan to Cut Drug Prices by 0.86% in FY2026; Central Govt Savings Seen at 105 Billion Yen
December 25, 2025
- Japan Growth Strategy Council to Set Up Drug Discovery Working Group
December 25, 2025
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
- Japan Panel OKs Label Warning Update for Labor Inducers to Mention Epidural Births
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…